Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint

December 8, 2022

Biotechnology

MAIA Biotechnology Announces $1.00 Million Private Placement

April 23, 2024
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group

April 23, 2024
Nutriband Inc. Announces $8.4M Private Placement

April 19, 2024
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

April 18, 2024